|
|
|
|
Managing Directors |
Ron Eastman has over 30 years of experience in building healthcare businesses. He began his career at American Cyanamid Company, which was acquired by American Home Products (now Wyeth). At Cyanamid, Mr. Eastman spent 15 years managing various pharmaceutical products, divisions and subsidiaries in the U.S. and overseas. Since then, he has helped build three private healthcare companies -- Geron, HCORP, and Rinat Neuroscience. Under his leadership, Geron became a cutting-edge biotech company that grew from a venture-backed startup to a publicly traded pioneer in the fields of regenerative medicine and cancer. HCORP quickly established itself as the technology and market leader in the emerging field of hospital-based, interactive patient services and was sold to a diversified competitor. Most recently, at Rinat, a private biotech company spun out of Genentech in late 2001, Mr. Eastman led the effort to build the first company dedicated to discovering and developing large molecule drugs for treating nervous system disorders. Rinat was acquired by Pfizer in 2006.
Mr. Eastman joined Essex Woodlands in October 2006. He serves as Chairman of the
Board of Directors at
Elusys Therapeutics, Inc. He aso serves on the Boards of Corium
International, Revance Therapeutics, Inc, Open Monoclocnal Technology, Inc, (OMT) and on the Board of Trustees at The Buck Institute,
the largest non-profit research institute in the U.S. studying diseases
of aging.
Mr. Eastman earned his B.A. from
Williams College and his M.B.A. from Columbia University.
|
|
|
 |
|
|
|
